IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.
The in vivo requirements for human natural killer (NK) cell development and differentiation into cytotoxic effectors expressing inhibitory receptors for self-major histocompatibility complex class I (MHC-I; killer Ig-like receptors [KIRs]) remain undefined. Here, we dissect the role of interleukin (IL)-15 in human NK cell development using Rag2(-/-)gamma c(-/-) mice transplanted with human hematopoietic stem cells. Human NK cell reconstitution was intrinsically low in this model because of the poor reactivity to mouse IL-15. Although exogenous human IL-15 (hIL-15) alone made little improvement, IL-15 coupled to IL-15 receptor alpha (IL-15R alpha) significantly augmented human NK cells. IL-15-IL-15R alpha complexes induced extensive NK cell proliferation and differentiation, resulting in accumulation of CD16(+)KIR(+) NK cells, which was not uniquely dependent on enhanced survival or preferential responsiveness of this subset to IL-15. Human NK cell differentiation in vivo required hIL-15 and progressed in a linear fashion from CD56(hi)CD16(-)KIR(-) to CD56(lo)CD16(+)KIR(-), and finally to CD56(lo)CD16(+)KIR(+). These data provide the first evidence that IL-15 trans-presentation regulates human NK cell homeostasis. Use of hIL-15 receptor agonists generates a robust humanized immune system model to study human NK cells in vivo. IL-15 receptor agonists may provide therapeutic tools to improve NK cell reconstitution after bone marrow transplants, enhance graft versus leukemia effects, and increase the pool of IL-15-responsive cells during immunotherapy strategies.
Huntington
Nicholas D
ND
Immunology Department, 2 Institut National de la Santé et de la Recherche Médicale U668, 3 INSERM U883, Unité de Régulation Immunitaire et Vaccinologie, Institut Pasteur, Paris 75724, France. nhunting@pasteur.fr
Legrand
Nicolas
N
Alves
Nuno L
NL
Jaron
Barbara
B
Weijer
Kees
K
Plet
Ariane
A
Corcuff
Erwan
E
Mortier
Erwan
E
Jacques
Yannick
Y
Spits
Hergen
H
Di Santo
James P
JP
D000818:Animals; D000831:Animals, Newborn; D000943:Antigens, Differentiation / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004268:DNA-Binding Proteins / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D006801:Humans; D053631:Interleukin Receptor Common gamma Subunit / Q000235:genetics; D019409:Interleukin-15 / Q000008:administration & dosage / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008221:Lymphoid Tissue / Q000166:cytology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008819:Mice, Nude; D053647:Receptors, Interleukin-15 / Q000819:agonists / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic; D014183:Transplantation, Heterologous; D051020:bcl-X Protein / Q000235:genetics / Q000378:metabolism
D000943:Antigens, Differentiation; D004268:DNA-Binding Proteins; C508024:IL15RA protein, human; D053631:Interleukin Receptor Common gamma Subunit; D019409:Interleukin-15; C499308:Rag2 protein, mouse; D053647:Receptors, Interleukin-15; D011993:Recombinant Fusion Proteins; D051020:bcl-X Protein